Premium
Pharmacokinetics and Pharmacodynamics of Oral Nizatidine
Author(s) -
Vargas Ramon,
Ryan Jerome,
McMahon F. Gilbert,
Regel Gayle,
Offen Walter W.,
Matsumoto Charles
Publication year - 1988
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1988.tb03103.x
Subject(s) - cimetidine , pharmacokinetics , placebo , pharmacodynamics , gastric acid , medicine , meal , equivalent , pharmacology , antagonist , stomach , receptor , alternative medicine , pathology
Nizatidine was studied in six high‐acid‐secretor (basal secretion, ≥ 5 mEq/hr) male volunteers in a randomized, double‐blind, nonbalanced, cross‐over, placebo and standard drug‐controlled study. Doses of 75 mg, 150 mg, and 300 mg bid were compared with placebo and cimetidine 300 mg qid. Nocturnal acid output was significantly reduced (P < .01) by all doses of nizatidine (36 ± 22, 36 ± 31, and 26 ± 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 ± 39 mEq) as compared with placebo (101 ± 61 mEq). Nizatidine also significantly reduced meal‐stimulated acid secretion at breakfast (14 ± 9, 9 ± 7, and 5 ± 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P < .01), at lunch (50 ± 22, 57 ± 22 and 50 ± 35 mEq/2 hours, P < .05) but did not have any effect at dinner (65 ± 16,78 ± 24, and 71 ± 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P < .01) reduced meal‐stimulated acid secretion (25 ± 16, 27 ± 20 and 31 ± 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 ± 30, 76 ± 25, and 66 ± 16 mEq/2 hours, breakfast, lunch, and dinner, respectively). Both drugs have a similar pharmacokinetic profile. Nizatidine seems to be a promising H 2 antagonist, more potent than cimetidine (on an mg/mg basis), and efficacy studies on gastric acid disorders should be performed.